Fortrea Holdings Inc. Common Stock FTRE
i
Market dataready · fetched 2026-11-06T20:51:00.107Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T20:50:58.071263217Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-06T20:50:59.412176+00:00
Fortrea Holdings Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 24.81 | 68.5% | 14.9% | 18.67 | 104.4% | 17.2% |
| 25Δ | 24.30 | 66.1% | 13.0% | 19.41 | 102.6% | 14.6% |
| 30Δ | 23.79 | 63.8% | 11.1% | 20.09 | 99.6% | 12.2% |
| 35Δ | 23.28 | 61.4% | 9.2% | 20.53 | 92.1% | 10.5% |
| 40Δ | 22.76 | 59.1% | 7.3% | 20.98 | 84.6% | 8.9% |
| 45Δ | 22.31 | 59.3% | 6.0% | 21.42 | 77.1% | 7.2% |
| 50Δ | 21.93 | 62.4% | 5.4% | 21.86 | 69.6% | 5.6% |
| 55Δ | 21.54 | 65.4% | 4.9% | 22.30 | 62.0% | 4.0% |
| 60Δ | 21.15 | 68.5% | 4.3% | 22.91 | 64.2% | 3.1% |
| 65Δ | 20.76 | 71.6% | 3.7% | 23.65 | 74.2% | 2.9% |
| 70Δ | 20.38 | 74.6% | 3.2% | 24.40 | 84.2% | 2.6% |
| 75Δ | 19.98 | 77.4% | 2.6% | 25.27 | 94.3% | 2.3% |
| 80Δ | 19.44 | 73.1% | 2.1% | |||
20Δ
- Pseudo strike
- 24.81
- IV
- 68.5%
- B/E move
- 14.9%
- Pseudo strike
- 18.67
- IV
- 104.4%
- B/E move
- 17.2%
25Δ
- Pseudo strike
- 24.30
- IV
- 66.1%
- B/E move
- 13.0%
- Pseudo strike
- 19.41
- IV
- 102.6%
- B/E move
- 14.6%
30Δ
- Pseudo strike
- 23.79
- IV
- 63.8%
- B/E move
- 11.1%
- Pseudo strike
- 20.09
- IV
- 99.6%
- B/E move
- 12.2%
35Δ
- Pseudo strike
- 23.28
- IV
- 61.4%
- B/E move
- 9.2%
- Pseudo strike
- 20.53
- IV
- 92.1%
- B/E move
- 10.5%
40Δ
- Pseudo strike
- 22.76
- IV
- 59.1%
- B/E move
- 7.3%
- Pseudo strike
- 20.98
- IV
- 84.6%
- B/E move
- 8.9%
45Δ
- Pseudo strike
- 22.31
- IV
- 59.3%
- B/E move
- 6.0%
- Pseudo strike
- 21.42
- IV
- 77.1%
- B/E move
- 7.2%
50Δ
- Pseudo strike
- 21.93
- IV
- 62.4%
- B/E move
- 5.4%
- Pseudo strike
- 21.86
- IV
- 69.6%
- B/E move
- 5.6%
55Δ
- Pseudo strike
- 21.54
- IV
- 65.4%
- B/E move
- 4.9%
- Pseudo strike
- 22.30
- IV
- 62.0%
- B/E move
- 4.0%
60Δ
- Pseudo strike
- 21.15
- IV
- 68.5%
- B/E move
- 4.3%
- Pseudo strike
- 22.91
- IV
- 64.2%
- B/E move
- 3.1%
65Δ
- Pseudo strike
- 20.76
- IV
- 71.6%
- B/E move
- 3.7%
- Pseudo strike
- 23.65
- IV
- 74.2%
- B/E move
- 2.9%
70Δ
- Pseudo strike
- 20.38
- IV
- 74.6%
- B/E move
- 3.2%
- Pseudo strike
- 24.40
- IV
- 84.2%
- B/E move
- 2.6%
75Δ
- Pseudo strike
- 19.98
- IV
- 77.4%
- B/E move
- 2.6%
- Pseudo strike
- 25.27
- IV
- 94.3%
- B/E move
- 2.3%
80Δ
- Pseudo strike
- 19.44
- IV
- 73.1%
- B/E move
- 2.1%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 82.75% | |
| 77.32% | |
| 85.31% | |
| 79.92% | |
| 78.81% | |
| 78.04% | |
| 81.27% | |
| 79.28% | |
| 78.24% | |
| 77.99% | |
| 79.22% | |
| 75.78% | |
| 77.81% | |
| 77.07% | |
| 86.35% | |
| 89.35% | |
| 83.22% | |
| 95.36% | |
| 84.93% | |
| 84.01% | |
| 77.92% | |
| 81.83% | |
| 76.53% | |
| 77.41% | |
| 78.01% | |
| 76.90% | |
| 81.63% | |
| 75.54% | |
| 77.72% | |
| 81.89% | |
| 79.86% | |
| 81.51% | |
| 80.42% | |
| 76.91% | |
| 88.11% | |
| 96.39% | |
| 104.48% | |
| 80.19% | |
| 83.32% | |
| 81.72% | |
| 81.39% | |
| 83.05% | |
| 85.02% | |
| 87.16% | |
| 83.84% | |
| 85.53% | |
| 76.97% | |
| 77.11% |
Biotechnology
FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined diseases in areas…
More →GALT
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The…
More →GANX
Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding. The company is…
More →GENB
Generate Biomedicines, Inc. is an innovative biotechnology company at the forefront of protein therapeutics development, leveraging advanced genetic engineering and artificial…
More →GERN
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The…
More →GHRS
Description unavailable
More →